相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
Steven M. Horwitz et al.
BLOOD (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
Laura Quan Man Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting CD47 in Sezary syndrome with SIRPαFc
Lisa D. S. Johnson et al.
BLOOD ADVANCES (2019)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.
Nehal J. Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Interim Results of a Multicenter Phase I Trial
Christiane Querfeld et al.
BLOOD (2018)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova et al.
CLINICAL CANCER RESEARCH (2017)
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets
Gloria H. Y. Lin et al.
PLOS ONE (2017)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson et al.
BLOOD (2016)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona et al.
BLOOD (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Wendy W. Pang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P. Chao et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
D. Kim et al.
LEUKEMIA (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
Mark P. Chao et al.
BLOOD (2011)
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Mark P. Chao et al.
CANCER RESEARCH (2011)
Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients
Makoto Nagahara et al.
CLINICAL CANCER RESEARCH (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
